Clinical Trial

Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients

Name: Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients — clinical trial record (NCT07597941)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

This study is to assess the efficacy and safety of Lisaftoclax for prevention of DS in APL patients undergoing ATRA/ATO induction regimen.

Protocol Amendment History 1 change

notable Enrollment reduced: 60 -> 20 participants 2026-07-01

Trial Details

NCT Number	NCT07597941
Lead Sponsor	The Affiliated People's Hospital of Ningbo University
Conditions	Acute Promyelocytic Leukemia (APL)
Enrollment	20 participants
Start Date	2026-07
Primary Completion	2028-06 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-30